Skip to content
drillr.ai

CDNA

CareDx, Inc

NASDAQ · USHealthcareMedical - Diagnostics & Research
$38.37-3.42%

Price as of Jul 20, 2026

CDNA news

CareDx, Inc news

A server-rendered, paginated timeline of the latest available company news.

  1. CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

    CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Eve

    Business Wire ·

  2. CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

    CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology NavDx(®) is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its

    Business Wire ·

  3. CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific

    CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its L

    Business Wire ·

  4. CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress

    CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress Growing body of evidence supports AlloSure(®) as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes Data across kidney, heart, lung, and multi-organ transplantation; featuring new KOAR prognostic findings and ImmuneScape™ single cell and spatial transcriptomics rejection classification advances CareDx, Inc. (Nasdaq: CDNA)

    Business Wire ·

  5. CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology

    CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology AlloSure(®) Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data support the role of AlloSure(®) Kidney as a noninvasive tool for longitudinal risk stratification and clinical decision-making CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and co

    Business Wire ·

  6. CareDx to Participate in Upcoming Investor Conferences

    CareDx to Participate in Upcoming Investor Conferences CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: * Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on

    Business Wire ·

  7. CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restr

    Business Wire ·

  8. CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting

    CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46(th) Annual Meeting Breadth of Data Demonstrates the Important Role of Precision Medicine Testing in Post-Transplant Monitoring and Decision Making New SHORE Data Highlights Significance of Early Molecular Signals in Heart Transplant and New ALAMO Data Highlights Significance of Longitudinal Risk Assessment in Lung Transplantation CareDx,

    Business Wire ·

  9. CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

    CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories. CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions

    Business Wire ·

  10. CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results

    CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results Transaction Expected to Sharpen CareDx’s Focus on Core Precision Medicine Testing Services and Patient and Digital Solutions, Improve Financial Flexibility, Simplify Operating Model, and Support AEBITDA Margin Expansion Expects First Quarter Testing Services Revenue Growth of Approximately 48% Year Over Year, Testing Volume Growth of Approx

    Business Wire ·

  11. CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

    CareDx to Report First Quarter 2026 Financial Results on April 28, 2026 CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference ca

    Business Wire ·